COVID-19 Vaccination During Pregnancy May Significantly Reduce Preeclampsia Risk, Study Finds

Global - Ekhbary News Agency

COVID-19 Vaccination During Pregnancy Linked to Lower Preeclampsia Risk

[City, Country] – Pregnant individuals who receive COVID-19 vaccines may experience a substantially lower risk of developing preeclampsia, a dangerous pregnancy complication characterized by high blood pressure, according to a large-scale study. The research, which analyzed data from over 6,500 mothers, suggests that vaccination against the SARS-CoV-2 virus offers a protective effect against this serious hypertensive disorder, a finding that could significantly influence prenatal care guidelines.

Preeclampsia affects an estimated 3% to 8% of pregnancies and typically manifests in the latter half of gestation or shortly after delivery. Its hallmark is persistently high blood pressure, often accompanied by protein in the urine, indicating potential kidney damage. The condition can lead to severe maternal and fetal complications, including damage to vital organs like the liver and kidneys, cardiovascular strain, and placental insufficiency. In its most severe form, preeclampsia can progress to eclampsia, characterized by seizures and potentially coma, posing a life-threatening risk to both mother and baby. The exact causes of preeclampsia remain elusive, though research points to factors like abnormal placental development and potentially the influence of viral infections.

The COVID-19 pandemic highlighted the vulnerabilities of pregnant individuals, with studies consistently showing that contracting the virus during pregnancy can lead to adverse outcomes. This new research builds upon that understanding by quantifying the increased risk of preeclampsia associated with COVID-19 infection itself. The findings indicate that pregnant women who contracted COVID-19 during the pandemic faced a 45% higher risk of developing preeclampsia compared to their non-infected counterparts. This risk was even more pronounced among unvaccinated women, who saw their preeclampsia risk surge by 78% if they contracted the virus.

Conversely, the study observed a significant protective effect from vaccination. Women who completed their primary COVID-19 vaccination series and received an updated booster shot experienced an overall 33% reduction in their risk of developing preeclampsia. This protective benefit was amplified for those with pre-existing medical conditions, such as diabetes. In this subgroup, receiving a booster dose was associated with a 58% decrease in preeclampsia risk. Dr. José Villar, a professor of perinatal medicine at the University of Oxford and a co-lead author of the study, described these findings as potentially "breakthrough" in understanding the intricate links between viral infections and preeclampsia.

The researchers theorize that COVID-19 vaccines might mitigate preeclampsia risk through several mechanisms. Primarily, vaccination reduces the likelihood of contracting COVID-19 or experiencing severe illness from the infection, thereby removing a known trigger for the condition. Additionally, the study authors suggest that vaccination could bolster the immune system more broadly, potentially offering protection against other infections and improving vascular health, which is crucial for preventing preeclampsia.

The study, published in the journal *eClinicalMedicine*, analyzed data collected from over 6,500 pregnant women across 18 countries between 2020 and 2022. Approximately one-third of the participants were diagnosed with COVID-19 during their pregnancy. A significant portion, about 58%, were unvaccinated at the time their data was collected. Among the vaccinated participants, around 31% had received a booster dose in addition to their initial vaccination series.

Beyond the reduction in preeclampsia risk, the findings indicated that vaccination, particularly with booster doses, was associated with better overall pregnancy outcomes. Women who received booster shots exhibited lower rates of adverse events, such as preterm birth and admission to intensive care units, compared to unvaccinated women. This aligns with prior research from 2024, which found that women receiving at least one COVID-19 vaccine dose were less likely to experience preterm birth, stillbirth, or deliver a baby small for gestational age.

Dr. Elena Raffetti, an assistant professor at the Karolinska Institute in Sweden and lead author of the aforementioned 2024 report, commented on the safety and efficacy of vaccines, stating, "Vaccinations are safe and are protective for several risks." She further clarified, "There was not at all an increased risk of preeclampsia among women who were vaccinated," reinforcing the safety profile of these vaccines in pregnant populations.

The authors of the current study emphasized that their findings strongly support existing recommendations from health organizations. The American College of Obstetricians and Gynecologists (ACOG) advises pregnant individuals to get an updated COVID-19 vaccine promptly, whether they are planning pregnancy, are in any trimester, or are breastfeeding.

While the study provides compelling evidence, the researchers acknowledged certain limitations. They made efforts to control for confounding factors like maternal age, smoking history, and pre-existing conditions such as hypertension and diabetes. However, they conceded that residual differences between the vaccinated and unvaccinated groups might still exist and could influence the observed risks. Future research is recommended to delve deeper into the immune system's response to both infections and vaccines in pregnancy, and to further elucidate why infections like COVID-19 appear to elevate preeclampsia risk.

Understanding the complex etiology of preeclampsia remains a critical area of medical research. This study adds a significant piece to the puzzle, highlighting vaccination as a potentially powerful tool in safeguarding maternal and fetal health against the dual threats of COVID-19 infection and preeclampsia.

Ekhbary News Agency